The Mapping America's Pharmaceutical Supply Act, or MAPS Act, seeks to improve Federal efforts in identifying and mitigating health and national security risks associated with essential medicines. It establishes a framework centered on three key components: maintaining an updated list of essential medicines, conducting a thorough risk assessment of their supply chains, and implementing a monitoring system to map these critical supply chains using data analytics. The bill directs the Secretary of Health and Human Services to update and maintain an Essential Medicines List , initially based on Executive Order 13944, to include drugs vital for responding to threats, those at high risk of shortage, or those whose absence would adversely affect chronic conditions. This list must be reviewed and updated at least every two years. Concurrently, a comprehensive risk assessment of these essential medicine supply chains is mandated, identifying key starting materials, reliance on foreign or single suppliers, domestic manufacturing capabilities, and public health and national security risks, including cybersecurity threats. This assessment will also outline Federal mitigation strategies and must be reported to Congress annually. Furthermore, the Act requires the Secretary to coordinate efforts to map and visualize pharmaceutical supply chains , from raw material manufacturing to distribution, for all drugs on the Essential Medicines List. This mapping will utilize data analytics to pinpoint supply chain vulnerabilities that pose threats to public health or national security. The Secretary must also facilitate information exchange among Federal agencies regarding manufacturing locations, production amounts, and regulatory actions, with annual reports to Congress detailing mapping progress, coordination efforts, and identified gaps or duplications. Robust cybersecurity measures are required to protect all shared information.